Overview

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. The objectives of this investigation are to assess the feasibility of switching from a DAPT to DPI regimen and to compare the pharmacodynamic profiles of these treatment regimens. This will be a prospective study conducted in cohorts of patients with CAD on treatment per standard of care with DAPT. Patients will be randomized to either maintain DAPT or to DPI. DPI consists in treatment with aspirin (81mg/qd) plus rivaroxaban (2.5mg/bid).

Phase:

Phase 4

Details

Lead Sponsor:

University of Florida

Collaborator:

Janssen, LP

Treatments:

Aspirin
Clopidogrel
Prasugrel Hydrochloride
Rivaroxaban
Ticagrelor